Search Results 141-150 of 22983 for Phase

1. Phase II Trial of Standard Chemotherapy +Various Proton Beam Therapy (PBT) Doses for Unresectable Stage 2/3 Non-Small Cell Lung Cancer - Mayo Clinic

   Phase II Trial of Standard Chemotherapy +Various Proton Beam Therapy (PBT) Doses for Unresectable Stage 2/3 Non-Small Cell Lung Cancer · Overview · Participation ...

2. Phase 1/2 Study Of MRTX1719 In Solid Tumors With MTAP Deletion - Mayo Clinic

   The purpose of this study is to to characterize the safety, tolerability, and pharmacokinetics of MRTX1719 in patients with advanced solid tumor malignancies ...

3. NRG-GY012 “A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5356 (Capivasertib) in Women with Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women with Recurrent or Persistent Endometrial Cancer” - Mayo Clinic

   The purpose of this randomized phase II trial study is to determine how well olaparib, cediranib maleate, and Week 1 inhibitor AZD1775 work in treating patients ...

4. VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM - Mayo Clinic

   This is an adaptive design, randomized controlled, Phase 3 clinical trial in patients with glioblastoma multiforme (GBM) or gliosarcoma (GS), previously treated ...

5. Phase 1/2, Open-label, Dose-escalation Study of ISIS-STAT3Rx, Administered to Patients with Advanced Cancers - Mayo Clinic

   This is a Phase 1/2, open-label, dose-escalation, dose-expansion study for the treatment of patients with advanced cancers. Eligible patients with DLBCL or ...

6. A Phase 3 Safety and Efficacy Study of Fovista™ (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy - Mayo Clinic

   A Phase 3 Safety and Efficacy Study of Fovista™ (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy · Overview.

7. A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults with Idiopathic Pulmonary Fibrosis - Mayo Clinic

   A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults with Idiopathic Pulmonary Fibrosis · Overview · Participation ...

8. Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy - Mayo Clinic

   The secondary efficacy objective is to assess the effects of natalizumab versus placebo in drug-resistant focal epilepsy on additional measures of seizure ...

9. A Phase III, Randomised Study Of Adjuvant Dato-DXd In Combination With Rilvegostomig Or Rilvegostomig Monotherapy Versus Standard Of Care, Following Complete Tumour Resection, In Participants With Stage I Adenocarcinoma NSCLC Who Are CtDNA-positive Or Have High-risk Pathological Features - Mayo Clinic

   A Phase III, Randomised Study Of Adjuvant Dato-DXd In Combination With Rilvegostomig Or Rilvegostomig Monotherapy Versus Standard Of Care, ...

10. Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients

    About this study. The small molecule, CWP232291, by binding Sam68 promotes apoptosis in selective cancer cells through 1)induction of the TNF-α apoptotic ...